 4D pharma PLC AIM:DDD, NASDAQ:LBPS said had finished recruitment of the first part of its phase III evaluation of MRx-4DP0004 in patients with partly controlled asthma. In all, 30 people with the condition have been enrolled on the 12-week study with top-line results expected in the second half of this year. 